Medicenna Therapeutics (TSE:MDNA) Sets New 12-Month Low – Should You Sell?

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) reached a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.36 and last traded at C$0.36, with a volume of 128723 shares changing hands. The stock had previously closed at C$0.37.

Medicenna Therapeutics Stock Down 2.7%

The company has a debt-to-equity ratio of 4.79, a current ratio of 1.52 and a quick ratio of 4.65. The firm’s 50-day moving average price is C$0.46 and its 200 day moving average price is C$0.68. The firm has a market capitalization of C$33.23 million, a price-to-earnings ratio of -1.64 and a beta of 2.96.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings results on Thursday, June 25th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. Sell-side analysts expect that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.